scholarly journals Levels of plasma cell-free DNA and its correlation with disease activity in rheumatoid arthritis and systemic lupus erythematosus patients

2016 ◽  
Vol 38 (4) ◽  
pp. 295-300 ◽  
Author(s):  
Ibrahim T. Abdelal ◽  
Mohammad A. Zakaria ◽  
Doaa M. Sharaf ◽  
Ghada M. Elakad
RMD Open ◽  
2021 ◽  
Vol 7 (3) ◽  
pp. e002010
Author(s):  
Stavros Giaglis ◽  
Douglas Daoudlarian ◽  
Reinhard E Voll ◽  
Diego Kyburz ◽  
Nils Venhoff ◽  
...  

ObjectivesCell-free DNA is involved in the pathogenesis of systemic lupus erythematosus (SLE) but the clinical value of cell-free DNA measurements in SLE is unknown. Our aim was therefore to examine the utility of mitochondrial (mt) DNA and nuclear (n) DNA quantification in SLE.MethodsEDTA plasma was drawn from 103 consecutive patients with SLE and from 56 healthy blood donors. mtDNA and nDNA copy numbers were quantified by PCR from cell-free plasma. Clinical parameters were recorded prospectively.ResultsCirculating mtDNA copy numbers were increased 8.8-fold in the plasma of patients with SLE (median 6.6×107 /mL) compared with controls (median 7.6×106 /mL, p<0.0001). Among all 159 individuals, a cut-off set at 1.8×107 mtDNA copies in a receiver operated curve identified patients with SLE with 87.4% sensitivity and 94.6% specificity; the area under the curve was 0.95 (p<0.0001). mtDNA levels were independent of age or gender, but correlated with Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) on multivariable analysis (p=0.004). Conversely, SLEDAI was associated with prednisone dose (p<0.001), anti-double stranded DNA-titres (p=0.003) and mtDNA levels (p=0.005), but not nDNA copy numbers. In 33 patients with SLE with available follow-up, the changes of mtDNA, but not those of nDNA concentrations, robustly correlated with the evolution of the SLEDAI (r=0.55, p=0.001).ConclusionsCirculating mtDNA unlike nDNA molecules are markedly increased in SLE plasma. Regardless of disease activity, circulating mtDNA levels distinguish patients with SLE from healthy controls with high sensitivity and represent an independent marker of SLE activity.


2014 ◽  
Vol 292 (1-2) ◽  
pp. 32-39 ◽  
Author(s):  
Suzan Tug ◽  
Susanne Helmig ◽  
Julia Menke ◽  
Daniela Zahn ◽  
Thomas Kubiak ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Moshiur Rahman Khasru ◽  
Md Abu Bakar Siddiq ◽  
Kazi Mohammad Sayeeduzzaman ◽  
Tangila Marzen ◽  
Abul Khair Mohammad Salek

A 37-year-old Bangladeshi woman presented with low back and several joints pain and swelling for months together; there was significant morning stiffness for more than two hours. Repeated abortions, dry eye, hair fall, photosensitivity, and oral ulcer were the additional complaints. Clinical examination unveiled asymmetrical peripheral and both sacroiliac joint tenderness, positive modified Schober’s test, and limited chest expansion. Schirmer’s test was positive. The history of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) among 1st-degree relatives was also significant. Biochemical analysis revealed pancytopenia, raised erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and mild microscopic proteinuria. The patient was seropositive for rheumatoid factor (RF), antibodies against cyclic citrullinated peptides (anti-CCP), antinuclear antibody (ANA), anti-Sm antibody, anti-Sjögren’s-syndrome-related antigen A and B (anti-SSA/SSB), antiphospholipid (aPL-IgG/IgM), and HLA B27; however, serum complement (C3 and C4) levels were normal. Basal cortisol level measured elevated. Besides, X-ray and MRI of lumbosacral spines demonstrated sacroiliitis. There was radiological cardiomegaly, echocardiography unveiled atrial regurgitation, and ascending aorta aneurysm. Based on the abovementioned information, RA, AS, and systemic lupus erythematosus (SLE) have been diagnosed. Moreover, the patient developed Sjogren’s syndrome (SS), antiphospholipid lipid syndrome (APS), Cushing syndrome, ascending aorta aneurysm, and atrial regurgitation. Her disease activity score for RA (DAS28), DAS for AS (ASDAS), SLE disease activity index (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) scores were 3.46, 2.36, 23, and 5, respectively. The patient received hydroxychloroquine (200 mg daily), pulsed cyclophosphamide, prednisolone (20 mg in the morning), and naproxen 500 mg (twice daily). To our best knowledge, this is the first report documenting RA, AS, and SLE with secondary SS and APS.


2016 ◽  
Vol 17 (1) ◽  
pp. 79-85 ◽  
Author(s):  
Olfat M. Hendy ◽  
Tawfik Abdel Motalib ◽  
Mona A. El Shafie ◽  
Fatma A. Khalaf ◽  
Sobhy E. Kotb ◽  
...  

2019 ◽  
Vol 25 (3) ◽  
pp. 285-290
Author(s):  
Mohammad Hassan El-Gawish ◽  
Doaa Mohamed Sharaf ◽  
Nermin Raafat Abdel-Fattah ◽  
Salwa Abdelaziz Rashed

Sign in / Sign up

Export Citation Format

Share Document